Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

In today’s heightened enforcement environment, compliance auditing isn’t just a best practice—it’s a necessity. Federal and ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to bet on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech ...

While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved. But now, an initiative spearheaded by Takeda is starting to shift the dial.

Pre-Open Stock Movers: Hemisphere Media Group, Inc. (NASDAQ:HMTV) 80% HIGHER; entered into a definitive agreement to be acquired ...

Arv­inas and Pfiz­er’s tar­get­ed pro­tein de­grad­er has not man­aged to dis­tin­guish it­self from oth­er, sim­i­lar breast can­cer drugs, ac­cord­ing to piv­otal da­ta re­ ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...